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Dachshund homolog 1 (DACH1), a key cell fate determination factor, contributes to tumorigenesis,
invasion, metastasis of human breast neoplasm. However, the exact molecular mechanisms for the
anti-tumor roles of DACH1 in breast carcinoma are still lack of extensive understanding. Herein,
we utilized immunohistochemistry (IHC) staining and public microarray data analysis showing that
DACH1 was higher in normal breast, low-grade and luminal-type cancer in comparison with breast
carcinoma, high-grade and basal-like tumors respectively. Additionally, both correlation analysis of
public databases of human breast carcinoma and IHC analysis of mice xenograft tumors demonstrated
that DACH1 inversely related to cancer stem cells (CSCs) markers, epithelial-mesenchymal transition
(EMT) inducers and basal-enriched molecules, while cluster of differentiation 44 (CD44) behaved in an
opposite manner. Furthermore, mice transplanted tumor model indicated that breast cancer cells Met-1
with up-regulation of DACH1 were endowed with remarkably reduced potential of tumorigenesis.
Importantly, meta-analysis of 19 Gene Expression Omnibus (GEO) databases of breast cancer implicated
that patients with higher DACH1 expression had prolonged time to death, recurrence and metastasis,
while CD44 was a promising biomarker predicting worse overall survival (OS) and metastasis-free
survival (MFS). Collectively, our study indicated that CD44 might be a novel target of DACH1 in breast
carcinoma.
In spite of significant achievement made in early diagnosis and therapeutic strategies, breast cancer still draws
great attention from the worldwide because of its high incidence rate and mortality1–3. The unsatisfactory clinical
outcome is mostly due to tumor recurrence, metastasis and therapy-resistance1. Identifying novel biomarkers
related to molecular subtypes, aggressive phenotypes and prognosis of breast cancer is essential for drug development, disease surveillance and precise therapy.
The retinal determination gene network (RDGN), including DACH1, EYA1 and SIX1, plays crucial roles in
the development of multiple organs4. SIX1 and EYA1, two important RDGN members, exert favorable effects
on tumor initiation and progression4, 5, and high expression of SIX1 and EYA1 is an adverse factor for clinical outcomes for breast cancer patients6–8. On the contrary, another key RDGN member DACH1 behaved
as a tumor suppressor and reduced expression of DACH1 predicts poor survival performance of breast cancer patients9. Several lines of evidence have demonstrated that the hypermethylation of promoter region leads
to the down-regulation of DACH1, which is closely associated with proliferation, invasion and metastasis of
various tumors, including breast cancer10–13, lung cancer14, esophageal cancer15, renal cell carcinoma16 and
hepatocellular carcinoma17. DACH1 antagonizes the transcription and translation of oncogenes and induces
epithelial-mesenchymal transition (EMT) in breast cancer, resulting in the inhibition of tumor growth, invasion
and migration9, 10. Recent studies prove that cancer stem cells (CSCs) possess potent self-renewal ability and are
responsible for tumor relapse and metastasis and endogenous DACH1 participates in the negative regulation of
CSCs18, 19.
Cluster of differentiation-44 (CD44), a ubiquitously present glycoprotein on the membrane of mammalian
cells, plays essential roles in a variety of biological function such as cell division, adhesion and migration 20.
During the past decades, the role of CD44 in cancer development has been revealed and valued. As a well-known
marker of CSCs, CD44 promotes carcinogenesis, invasion, metastasis and therapy-resistance20–23. It promotes
proliferation and suppresses apoptosis by regulation of relative pathways, including Ras-Raf-Mek-Erk-Cyclin D1
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Figure 1. DACH1 and CD44 were correlated with tumorigenesis and histological grade of breast carcinoma.
(a) Representative images of immunohistochemistry staining of DACH1 and CD44 in noncancerous and
cancerous tissues were shown. (b) Representative images of immunohistochemistry staining of DACH1 and
CD44 in low-grade and high-grade breast neoplasm tissues were shown.

pathway and phosphoinositide 3-kinase (PI3K)-Akt signaling, as well as stimulates EMT, which contributes to
tumor invasion and metastasis20, 24.
Previous study has demonstrated that endogenous reduction of DACH1 was accompanied by down-regulation
of CSC markers, such as SOX2, Nanog, KLF418. To further evaluate the correlation between DACH1 and CSC
markers and EMT inducers in breast cancer, we performed a comprehensive analysis of immunohistochemistry
(IHC) staining, publicly available microarray data, RNA profiling and western blot. Our study indicated that
DACH1 was inversely correlated with CD44 and CD44 might be a novel target of DACH1 in breast cancer.

Results

DACH1 and CD44 associated with tumorigenesis and histological grade of breast cancer. In
order to evaluate the expression of DACH1 and CD44 in normal breast and breast malignant tissues, we carried
out IHC analysis on two TMAs (BR1502–97 and BR1502-98) with normal breast and human breast cancer tissues. DACH1 was majorly found in nucleus and CD44 was mostly detected on the membrane of breast cancer
cells. Representative images of IHC staining for noncancerous and cancerous tissues were shown in Fig. 1a, showing that DACH1 decreased and CD44 increased in breast neoplasm tissues in comparison with normal breast.
Additionally, we also explored the correlation between the protein abundance of DACH1 and CD44 and histological grade. Representative images of IHC staining for low-grade and high-grade cancerous tissues were showed
in Fig. 1b, which indicating that DACH1 was inversely correlated with tumor grade, while CD44 was positively
associated with histological grade.
Expression of DACH1 and CD44 correlated with molecular subtypes of breast cancer. We also
carried out IHC staining to assess the protein abundance of DACH1 and CD44 in luminal-type and basal-like
Scientific Reports | 7: 4361 | DOI:10.1038/s41598-017-04709-2
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Figure 2. The expression of DACH1 and CD44 correlated with molecular subtypes of breast carcinoma. (a)
Representative images of immunohistochemistry staining of DACH1 and CD44 in luminal-type and basallike breast cancer tissues were shown. (b) Expression analysis of public microarray dataset GSE20711 showed
that the mRNA level of DACH1 was significantly higher in luminal-type than in basal-like breast tumor. (c)
Expression analysis of GSE 20711 also displayed that CD44 mRNA expression was remarkably lower in luminaltype than in basal-like breast cancer.

breast cancer tissues. Representative images for the expression of DACH1 and CD44 in luminal and basal
tissues were shown in Fig. 2a. Furthermore, expression analysis of GSE20711 including a total of 45 luminal
and 22 basal-like breast tumor cases was also interrogated to evaluate the mRNA levels of DACH1 and CD44
in luminal and basal-like breast neoplasm tissues, which showed that DACH1 was enriched in luminal breast
carcinoma in comparison with basal-like breast cancer (P < 0.001) (Fig. 2b), while CD44 exhibited an opposite
tendency (P < 0.001) (Fig. 2c) at mRNA level. Altogether, our results indicated that luminal breast carcinoma
was most likely to be DACH1high/CD44low type, and basal-like breast tumor tissues were majorly DACH1low/
CD44high type.

DACH1 down-regulated some CSC and EMT markers in vitro, as well as blocked Met-1 tumor
growth in vivo. Breast cancer Met-1 cells were transducted with a DACH1 expression vector resulting in an

∼4.5-fold increase in DACH1 expression (Fig. 3a) and subsequent reduction of CSC markers CD44, KLF4 and
MYC as well as EMT markers including FN1 and VIM (Fig. 3b) by mRNA analysis. Western blot also demonstrated the presence of the DACH1-tagged FLAG epitome, and the effects of DACH1 overexpression on the protein abundance of CD44, Fibronectin, Vimentin, p21 and p27, which were showed in Fig. 3c. Ectopic expression
of DACH1 contributed to remarkable reduction of CD44, Fibronectin, Vimentin and significant up-regulation of
p21 and p27 in Met-1 cells. Mammary tumor growth in vivo was assessed by subcutaneous implantation of Met-1
cells in nude mice (Fig. 3f). Met-1 cells with engineered expression of DACH1 were endowed with remarkably
reduced potential of tumorigenesis in xenograft tumors. Up-regulation of DACH1 significantly reduced the volume of tumors by ∼90% and slowed down tumor growth (Fig. 3d). Tumor weight was also reduced by ∼90% in
comparison with the control tumors (Fig. 3e). The results implicated that DACH1 suppressed the expression of
some CSCs and EMT markers and serves as a potent anti-tumor factor in xenograft tumors.
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Figure 3. DACH1 regulated the expression of some CSCs and EMT genes in Met-1 cells and suppressed
tumor growth in vivo. (a) Stable expression of DACH1 in breast cancer Met-1 cells was achieved by retrovirus
infection. (b) RNA microarray and cluster analysis showed that upregulation of DACH1 reduced the mRNA
levels of CD24, CD44, KLF4, MYC, FN1 and VIM in Met-1 cells. (c) Western blot indicated that upregulation
of DACH1 reduced the protein abundance of CD44, Fibronectin, Vimentin, p21 and p27 in Met-1 cells. (d)
DACH1 overexpression significantly reduced the volume of tumors by ∼90% and slowed down the speed of
tumor growth in nude mice xenograft tumors. (e) Overexpression of DACH1 also reduced mice transplanted
tumor weight by ∼90%. (f) Mammary tumor growth in vivo was evaluated by subcutaneous implantation of
DACH1-overexpressing Met-1 cells and the GFP controls in nude mice.

DACH1 reduced the expression of CD44, Fibronectin, Vimentin, Myc, Sox2, EGFR, Ki-67 in
vivo. Immunohistochemistry analysis was conducted to assess the protein abundance of DACH1, CD44, Myc,

Sox2, Fibronectin, Vimentin, EGFR, Ki-67 in nude mice xenograft tumor tissues with overexpression of DACH1
and the GFP controls. Additionally, we also employed IHC scoring to quantize the levels of these proteins in both
DACH-overexpressing and the control tumors by using semi-quantitative criteria. About six 200 magnification
images of each kind of protein were selected for IHC scoring by two experienced pathologists independently.
Representative images of IHC staining and scoring results for DACH1, CD44, Myc, Sox2, Fibronectin, Vimentin,
EGFR and Ki-67 were shown in Fig. 4a,b,c,d,e,f,g and h, respectively. Our results displayed that over-expression of
DACH1 (P < 0.001) remarkably reduced the expression of CD44 (P < 0.001), Myc (P < 0.001), Sox2 (P < 0.001),
Fibronectin (P < 0.001), Vimentin (P < 0.001), EGFR (P < 0.001) and Ki-67 (P < 0.001), demonstrating that
DACH1 could potently down-regulated the expression of some CSCs and EMT markers, basal-like factor EGFR
and proliferative biomarker Ki-67 in vivo at protein level.
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Figure 4. DACH1 reduced the expression of CD44, Myc, Sox2, Fibronectin, Vimentin, EGFR and Ki-67 in vivo.
Both representative immunohistochemistry images and scoring results showed that overexpression of DACH1
(a) down-regulated the protein abundance of CD44 (b), Myc (c), Sox2 (d), Fibronectin (e), Vimentin (f), EGFR
(g) and Ki-67 (h) in nude mice xenograft tumors.

Correlation between the expression of DACH1 and CD44 and the levels of FN1, VIM, YBX1,
FOXA1, EGFR and MKI67. Previous study has implicated that DACH1 enriched in luminal A breast can-

cer and its expression fluctuated in direct proportion to the level of luminal-like marker FOXA113. Previously
experimental study demonstrated that DACH1 participated in the inhibition of Snail-induced EMT through
suppressing the activity of the Y box-binding protein (YB-1)9. Herein, public dataset GSE20685 was interrogated
to assess the association between DACH1 and CD44, FN1, VIM, FOXA1, EGFR and MKI67, as well as evaluate the
correlation between CD44 and the above genes. The results showed that DACH1 mRNA expression was inversely
correlated with CD44 (R = −0.341, P < 0.001) (Fig. 5a), FN1 (R = −0.214, P < 0.001) (Fig. 5b), VIM (R = −0.229,
P < 0.001) (Fig. 5c), EGFR (R = −0.390, P < 0.001) (Fig. 5e) and MKI67 (R = −0.376, P < 0.001) (Fig. 5f), but
Scientific Reports | 7: 4361 | DOI:10.1038/s41598-017-04709-2
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Figure 5. The expression of DACH1 and CD44 correlated with VIM, FN1, YBX1, FOXA1, EGFR and MKI67
in breast cancer tissues. Correlation analysis of public dataset GSE 20685 showed that DACH1 was inversely
correlated with cancer stem cell marker CD44 (a), mesenchymal markers FN1 (b) and VIM (c) as well as basal-like
markers EGFR (e) and MKI67 (f), while positively associated with luminal marker FOXA1 (d). CD44 was parallel
with FN1 (g) and VIM (h), YBX1 (i), EGFR (k) and MKI67 (l), while negatively associated with FOXA1 (j).

positively associated with the mRNA expression of FOXA1 (R = 0.608, P < 0.001) (Fig. 5d). Conversely, CD44 was
found to be positively correlated with FN1 (R = 0.253, P < 0.001) (Fig. 5g), VIM (R = 0.237, P < 0.001) (Fig. 5h),
YBX1 (R = 0.446, P < 0.001) (Fig. 5i), EGFR (R = 0.336, P < 0.001) (Fig. 5k) and MKI67 (R = 0.215, P < 0.001)
(Fig. 5l), while there was a significantly negative association between CD44 and FOXA1 (R = −0.402, P < 0.001)
(Fig. 5j).
Breast cancer cell line data reported by Neve RM25, including a total of 51 different breast cancer lines from
luminal-type (N = 25) or basal-like (N = 26), were also employed to evaluate the correlation between the expression of DACH1 and CD44 and the levels of FN1, VIM, YBX1, FOXA1, EGFR and MKI67. The results displayed
Scientific Reports | 7: 4361 | DOI:10.1038/s41598-017-04709-2
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Figure 6. The association between the expression of DACH1 and CD44 with VIM, FN1, YBX1, FOXA1, EGFR
and MKI67 in breast cancer cell lines. Correlation analysis of data with a total of 51 breast cancer cell lines
showed that DACH1 was inversely correlated with CD44 (a), FN1 (b), VIM (c), EGFR (e) and MKI67 (f), while
positively associated with FOXA1 (d). In contrast, CD44 was parallel with FN1 (g), VIM (h), YBX1 (i), EGFR (k)
and MKI67 (l), but negatively related to FOXA1 (j).

that DACH1 mRNA expression was inversely correlated with CD44 (R = −0.507, P < 0.001) (Fig. 6a), FN1
(R = −0.354, P = 0.011) (Fig. 6b), VIM (R = −0.419, P = 0.002) (Fig. 6c), EGFR (R = −0.523, P < 0.001) (Fig. 6e)
and MKI67 (R = −0.336, P = 0.016) (Fig. 6f) but positively associated with the mRNA level of FOXA1 (R = 0.539,
P < 0.001) (Fig. 6d), which were consistent with the results got in GSE20685. In contrast, CD44 was parallel with
FN1 (R = 0.406, P = 0.003) (Fig. 6g), VIM (R = 0.614, P < 0.001) (Fig. 6h), YBX1 (R = 0.557, P < 0.001) (Fig. 6i),
EGFR (R = 0.506, P < 0.001) (Fig. 6k) and MKI67 (R = 0.391, P = 0.005) (Fig. 6l) but negatively associated with
FOXA1 (R = −0.689, P < 0.001) (Fig. 6j), supporting the conclusion from the correlation analysis of human breast
tumor samples (GSE20685).
Scientific Reports | 7: 4361 | DOI:10.1038/s41598-017-04709-2
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First Author

GSE
accession

Year

Duration
(Months)

Patient
Number

Detection

Platform

Desmedt C26

GSE7390

2007

163.2

198

Microarray

GPL96

Pawitan Y27

GSE1456

2005

102

159

Microarray

GPL96

Hennessy BT28

GSE10885

2009

106

89

Microarray

GPL887

Dedeurwaerder S29

GSE20711

2011

169

88

Microarray

GPL570

Kao KJ30

GSE20685

2011

156

327

Microarray

GPL570

Clarke C31

GSE42568

2013

100.9

104

Microarray

GPL570

Desmedt C32

GSE16446

2011

60

120

Microarray

GPL570

Loi S33

GSE6532

2010

176.8

327

Microarray

GPL96

Bild AH34

GSE3143

2006

156

158

Microarray

GPL8300

Terunuma A35

GSE39004

2014

120

61

Microarray

GPL6244

Heikkinen T36

GSE24450

2011

120

183

Microarray

GPL6947

Hatzis C37

GSE25066

2011

120

508

Microarray

GPL96

Symmans WF38

GSE17705

2010

196

298

Microarray

GPL96

Wang Y39

GSE2034

2005

180

286

Microarray

GPL96

Tofigh A40

GSE58644

2014

145

321

Microarray

GPL6244

Minn AJ41

GSE2603

2005

130

99

Microarray

GPL96

Minn AJ42

GSE5327

2007

156

58

Microarray

GPL96

Sircoulomb F43

GSE17907

2010

112

51

Microarray

GPL570

Nagalla S44

GSE45255

2013

127.4

139

Microarray

GPL96

Table 1. Characteristics of the included public microarray datasets in the meta-analysis.

The opposite roles of DACH1 and CD44 in clinical outcomes of breast cancer patients.

In
order to assess the prognostic value of DACH1 and CD44 in breast cancer, a meta-analysis enrolling a total of
19 published Gene Expression Omnibus (GEO) databases and including 3574 breast cancer patients was performed26–44. The characteristics of these 19 GSE databases were displayed in Table 1. The results indicated that
patients with higher mRNA expression of DACH1 tended to enjoy longer time to death (HR: 0.72 (0.57–0.92),
I2 = 22.9%, P = 0.232) (Fig. 7a), relapse (HR: 0.73 (0.56–0.97), I2 = 64.1%, P = 0.003) (Fig. 7c) and metastasis
(HR: 0.73 (0.56–0.95), I2 = 27.2%, P = 0.202) (Fig. 7e). On the contrary, higher mRNA expression of CD44 was
directly related to worse OS (HR: 1.27 (1.03–1.57), I2 = 3.0%, P = 0.412) (Fig. 7b) and MFS (HR: 1.40 (1.02–
1.93), I2 = 48.4%, P = 0.050) (Fig. 7f), but did not insignificantly contribute to worse RFS (HR: 1.19 (0.94–1.51),
I2 = 45.7%, P = 0.056) (Fig. 7d). Our results demonstrated that DACH1 was a promising biomarker predictive of
better clinical outcomes, while CD44 was an adverse factor for the survival performance of breast cancer patients.

Discussion

DACH1, as an important member of RDGN, is widely expressed in epithelial cells and plays critical roles in
normal organ development45, 46. However, its absent or lower expression contributes to the initiation and progression of various tumor types, including lung adenocarcinoma14, pancreatic cancer47, breast cancer10 and gastric
cancer48. This study provided results that expression types of DACH1 and CD44 were opposite in breast cancer.
Overexpression of DACH1 reduced the levels of CSC and EMT markers in breast cancer cell line and potently
inhibited the ability of tumorgenesis in xenograft model. Besides, correlation analysis exhibited that DACH1
and CD44 behaved completely differently in the correlations with FN1, VIM, YBX1, FOXA1, EGFR and MKI67.
Importantly, DACH1 serves as a protective factor, while CD44 is an unfavorable element for the prognosis of
breast cancer patients. Thus, we concluded that DACH1 might exert inhibitory effects on the development of
breast cancer partly by suppression of EMT inducers and CSCs markers, especially CD44.
Carcinogenesis may derive from the acquisition of a plethora of oncogenic mutations, sequential suppression
of endogenous growth inhibitors49 and the loss control over pivotal cellular functions50. DACH1 accounts for the
carcinogenesis of various tumor types, including human breast cancer51. Previous studies have implicated that
DACH1 negatively regulated cellular proliferation and tumor growth by repressing cell cycle protein cyclin D1
in both breast cancer11 and renal clear cell cancer16. Restoration of DACH1 suppressed clone formation of renal
clear cell cancer cells in vitro as well as tumor growth in vivo through the inhibition of cyclin D1 transcription
via associating with AP-1 protein16. Furthermore, hypermethylation of DACH1 promoter region itself led to
carcinogenesis and it also exerted inhibitory effects on tumor initiation through activating transforming growth
factor-beta (TGF-beta) signaling15. Besides, DACH1 inhibited cellular growth in an NAD and p53-dependent
manner by direct protein-protein association in breast cancer52. On the contrary, CD44, a family of transmembrane glycoproteins, exerted promoting roles in tumorigenesis of various cancer types20. Up-regulation of the
cleaved intracellular domain of CD44 (CD44ICD) enriched the mammosphere formation, while the blockage of
CD44ICD reversed the effects53. Immunohistochemistry analysis on human breast cancer tissues and expression
analysis of GSE42568 indicated that CD44 remarkably increased in breast carcinoma in comparison with normal
breast tissues22. CD44 functions in carcinogenesis through binding to extracellular matrix components and messenger molecules in tumor environment54.
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Figure 7. DACH1 and CD44 were related to clinical outcomes of breast cancer patients. Meta-analysis of a
total of 19 public databases showed that breast cancer patients with higher DACH1 mRNA level tended to have
better overall survival (a), relapse-free survival (c), metastasis-free survival (e). On the contrary, patients with
higher CD44 mRNA expression had shorter time to death (b) and metastasis (f), but did not acquire statistically
significant worse relapse-free survival in comparison to patients with comparatively lower CD44 expression (d).

Several lines of evidence indicated that DACH1 expression correlated with tumor differentiation.
Immunohistochemistry analysis of clear cell renal cancer tissues displayed that DACH1 was inversely correlated
with tumor grade16. About 60% of cells in low-grade tumors expressed DACH1, and less than 20% cells in grade
III tumors expressed DACH116. Similar phenomenon was also found in breast cancer13. DACH1 was remarkably
enriched in low-grade breast tumors13. In contrast, CD44 positively correlated with breast tumor grade21, 22. Our
previous study displayed a positive association between CD44 expression and breast tumor grade at both mRNA
and protein levels21, 22. This paper further supported this opposite tendency of DACH1 and CD44 in low-grade
and high-grade breast carcinoma, respectively.
Majorly according to the status of ER, PR and Her2, breast cancer is grouped into four distinct subtypes
including luminal, Her2-positive, basal-type and normal-like. Among these, luminal tumor patients accounted
for the most part of breast carcinoma population and have relatively good clinical outcomes, while patients
Scientific Reports | 7: 4361 | DOI:10.1038/s41598-017-04709-2
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with basal-like tumor endowed with malignancy features have significantly poor prognosis. Previous study has
demonstrated that nuclear DACH1 is a biomarker of luminal breast cancer13. Breast tumors with positive ER–
alpha and co-expressing PR-alpha were most likely to highly express DACH1, and nuclear DACH1 expression
was positively correlated with luminal marker FOXA1 and inversely associated with basal-like markers EGFR13.
In contrast, our previous meta-analysis showed that CD44 mRNA was remarkably enriched in basal-like breast
cancer compared with luminal-type breast tumor21. CD44 was also positively correlated with basal markers
EGFR, KRT5 and KRT17, and inversely associated with luminal marker FOXA122. Our results supported that
luminal breast neoplasm tended to be with high DACH1 expression and low CD44 level, while basal-like tumors
were most likely to be the inverse type. The correlation analysis further indicated that DACH1 was significantly
inversely associated with CD44.
CSCs were composed of a subset of tumor cells with the expression of stem cell-associated markers and
enhanced capacity for tumorigenesis, metastasis and therapy-resistance55. It has been implicated that endogenous DACH1 participated in the negative regulation of CSCs18. DACH1 suppressed the expression of stem cell
markers SOX2, Nanog and KLF4 through binding to the promoters of these genes18. On the contrary, CD44, as a
well-known CSCs marker, positively monitored the levels of CSCs markers20. Nuclear location of cleaved CD44
intracellular domain transcriptionally activated stemness factors Nanog, Sox2 and Oct453.
EMT is a complex and highly conserved process which enhances cellular invasiveness, being critical for
metastasis of various solid tumors and considered to be promising therapeutic targets56. EMT was dysregulated by
a complex network during tumor development. Knock-down of DACH1 in breast cancer cells MCF-7 and T47D
promoted the morphology change from epithelial phenotype to mesenchymal pattern and interfered with cell–
cell contact, accompanied by down-regulation of epithelial marker E-cadherin, resulting in cell migration and
invasion10. DACH1 also transcriptionally suppressed the activity of Snail, leading to the activation of E-cadherin
in breast cancer cells10, but the complex of DACH1 and Snail could bind to the E-box of E-cadherin promoter
then contributing to the reduction of E-cadherin10. In addition, DACH1 reduced the expression of the mesenchymal marker Snail through suppressing the activity of the Y box-binding protein, an important EMT inducer9.
Besides, previous study has revealed that DACH1 decreased both in breast cancer cell lines and tissues accompanied by relatively high proportion of CSCs18. Inversely, CD44 not only promoted EMT, but also was upregulated
by some mesenchymal markers20. Previous studies have demonstrated that mesenchymal genes including ZEB1,
TWIST1, SNAI1 and SLUG were positively correlated with CD44 expression20. The switch from CD44 variant
isoforms to its standard isoform is essential to undergo EMT for normal epithelial cells57.
DACH1 played important roles in invasion and migration of various neoplasms, such as lung adenocarcinoma 14, gastric cancer 48, pancreatic cancer 47 and breast cancer 12. Several lines of evidence showed
that DACH1 is absent or suppressed in poor prognosis breast cancer58. Breast cancer patients with reduced
DACH1 expression had three years shorter time to death in comparison to those with normal DACH1 levels11.
Immunohistochemistry analysis showed that higher nuclear level of DACH1 was predictive of longer disease-free
interval, cancer relapse-free survival and distant metastasis-free survival over 5 years post diagnosis13. In consistence, our analysis of GSE databases showed that higher mRNA level of DACH1 was parallel with better OS, RFS
and MFS. The protected effect of DACH1 in the prognosis of breast cancer patients could be explained partly by
negatively interplaying CSCs and EMT10, 59. Besides, DACH1 inhibited breast cancer migration and invasion also
via suppressing oncogene function through targeting interleukin-812. Altogether, these studies suggested that
DACH1 could be a valuable molecular marker for prognosis, thereby detection of DACH1 level is useful for therapeutic stratification of breast cancer patients. In contrast, CD44 contributed to tumor formation and progression
predictive of poor clinical outcome20. CD44 functioned as an oncoprotein and knockdown of CD44 remarkably
attenuated the migration and invasion of breast cancer cells MDA-MB-231 and Hs578T by modulating c-Src
transcription60. According to the analysis of 448 primary breast tumors, CD44 was parallel with enhancive distant
recurrence and decreased disease-free survival61.
In this study, 19 public datasets were enrolled to assess the correlation between the mRNA levels of DACH1
and CD44 and the survival performance of breast cancer patients. However, there are still some limitations: 1)
the overall sample size is limited. Some data were not available when the meta-analysis was conducted; 2) the
platforms used to evaluate the mRNA expression of DACH1 and CD44 are different; 3) the results at the mRNA
levels might not be consistent with those at protein abundance because there is a complex regulation network
from mRNA to protein.
In conclusion, this study confirmed that DACH1 and CD44 inversely related in breast cancer, different grade
tumors and different subtypes. DACH1 was negatively associated with CD44 in vitro and vivo. DACH1 served as
a good prognostic marker, and CD44 was an unfavorable element of breast cancer patients. Thus, we concluded
that CD44 might be a novel target of DACH1.

Materials and Methods

Immunohistochemical staining.

To evaluate the expression of DACH1 and CD44 in normal breast versus breast tumor tissues, grade 1–2 versus grade 3 tissues as well as luminal-type and basal-like human breast
carcinoma tissues, two commercially available tissue microarray (TMA) slides (BR1502–97 and BR1502-98,
US Biomax, Inc, Rockville, MD) containing histologically confirmed tissues were purchased for immunohistochemistry (IHC) analysis. In addition, IHC was also employed to compare the expression of CD44, Fibronectin,
Vimentin, Sox2, Myc, EGFR and Ki-67 in Met-1 nude mice xenograft tumors with overexpression of DACH1 and
the controls. The Specific primary antibodies against DACH1 (10914-1-AP, ProteinTech Group), CD44 (15675-1AP, ProteinTech Group), Fibronectin (sc-8422, Santa Cruze), Vimentin (5741, Cell Signaling Technology), Sox2
(AB5603, Millipore), Myc (sc-40, Santa Cruze), EGFR (sc-03, Santa Cruze) and Ki-67 (ab15680, Abcam) were
utilized for IHC with a 2-step protocal62.
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Analysis and quantification of staining.

For quantification, a total of six 200× magnifications of each
kind of protein were selected for IHC scoring. Two experienced pathologists assessed the immunohistochemical
score independently. Scores were calculated on intensity and proportion of positive staining tumor cells in the
whole tissue stains according to the Fromowitz Standard as described above63. The staining intensity was scored
as 0 (no staining), 1 (weak staining, light yellow), 2 (moderate staining, yellow brown) and 3 (strong staining,
brown). The proportions of stained tumor cells were classified as 1 (0–25% positive cells), 2 (26–50% positive
cells), 2 (51–75% positive cells) and 3 (76–100% positive cells). The multiplication for intensity and proportion
was utilized to represent the protein levels of DACH1, CD44, Myc, Sox2, Fibronectin, Vimentin, EGFR and Ki-67.

Cell culture.

The breast cancer cell line Met-1, was cultured in high-glucose Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum (FBS, Life Technologies, Inc.). All cells were grown
37 °C in a humidified incubator with 5% CO2.

Western blot.

Cells were washed with cold PBS, scraped into RIPA buffer and centrifuged. The cell lysates
were subjected to 10% SDS-PAGE and transferred to a polyvinylidene fluoride (PVDF) hybridization transfer membrane. The primary antibodies used were as follows: HA (Sc-7392, Santa Cruze), CD44 (15675-1-AP,
ProteinTech group), Fibronectin (sc-8422, Santa Cruze), Vimentin (5741, Cell Signaling Technology), p21cip1
(sc-6246, Santa Cruze), p27kip2 (sc-1641, Santa Cruze) and β-actin (Sc-47778, Santa Cruze). Secondary staining
and detection were carried out in accordance with standard protocols16, 64.

RNA profiling by microarray.

DNA-free total RNA isolated from Met-1 cells expressing GFP or DACH1
were used to probe Affymetrix Gene 1.0 arrays (Affymetrix, Santa Clara, CA). RNA quality was determined by
gel electrophoresis. Analysis of the arrays was performed using GeneSpring. Arrays were normalized using robust
multi-array analysis, and the p value of 0.05 was applied as a statistical criterion for differentially expressed genes.

Meta-analysis for DACH1 on published Gene Expression Omnibus (GEO) databases.

We carried out a comprehensive search of relevant GEO databases for mRNA expression of DACH1 and CD44 through
ArrayExpress and Oncomine. The datasets meeting the following criteria were included: 1) the datasets were
about human breast cancer; 2) the mRNA expression of DACH1 and CD44 was measured in these databases; 3)
clinical outcomes of patients were showed in these databases; 4) the sample capacity was more than 50. Only the
latest and most complete datasets were included when several databases shared common patients. At last, a total
of 19 independent human breast cancer microarray databases with the mRNA expression of DACH1 and CD44
and required the survival information of breast cancer patients were enrolled in this systematic analysis.
Cutoff value for DACH1 and CD44 was median expression. OS, RFS and MFS were evaluated by Cox proportional hazard ratio (HR) and 95% confidence interval (95% CI). HRs was employed to assess the survival outcome of breast cancer patients with high mRNA expression of DACH1 and CD44 and HR >1 indicated that high
expression of DACH1 and CD44 predicted worse survival of patients. The random-effect model was employed
when heterogeneity was present, and the fixed-effect model was used when homogeneity was demonstrated.
Heterogeneity of publication was evaluated by means of the Chi-square-based-Q statistic and inconsistency index
(I2) statistic. Statistical analysis was performed based on the guidelines of Meta-Analysis of Observational Studies.
The STATA software package (version 12.0) (Stata Corp LP, College Station, TX, USA) was employed to perform
the meta-analysis.

Analysis of gene expression data.

GSE20711, available through GEO databases and containing 45
luminal-type and 22 basal-like breast carcinoma cases, was analyzed to evaluate the mRNA expression of DACH1
and CD44 in basal-like carcinoma in comparison with that in luminal-type tumors.
GSE20685, containing a total of 327 patients of breast cancer, was interrogated to assess the correlation
between DACH1 and CD44, FN1, VIM, FOXA1, EGFR, MKI67 as well as the correlation between CD44 and FN1,
VIM, YBX1, FOXA1, EGFR and MKI67 in breast cancer tissues.
Breast cancer cell line data of 51 breast cancer cell lines of different molecular subtypes published by Neve RM,
et al.25 were also employed to evaluate whether the correlation in breast cancer cells was consistent with that in
breast tumor tissues.

Nude Mice Study. The animal protocols were approved by the ethics committee of the Tongji Hospital of
Huazhong University of Science and Technology. The methods used in this section were in accordance with the
relevant guidelines and regulations. 1 × 105 Met-1 cells expressing GFP control or DACH1 were implanted subcutaneously into 4–6-week-old athymic female nude mice purchased from Wuhan Hamilton Biological Polytron
Technologies Inc. The tumor growth was measured twice weekly for 3 weeks by using a digital caliper. Tumor
weight was measured when mice were sacrificed on day 27 after cells implantation.
Statistical analysis.

Correlation analyses were performed using SPSS 20 statistical software (SPSS Inc.,
Chicago, IL, USA). The Student’s t-test was applied to evaluate the differences in groups as appropriate and the
significance level was set at 0.05. The correlation analysis was evaluated by a χ2- test. A two-tailed p value < 0.05
was considered statistically significant.
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